Controlling DNA-nanoparticle serum interactions

Proc Natl Acad Sci U S A. 2016 Nov 29;113(48):13600-13605. doi: 10.1073/pnas.1610028113. Epub 2016 Nov 16.

Abstract

Understanding the interaction of molecularly assembled nanoparticles with physiological fluids is critical to their use for in vivo delivery of drugs and contrast agents. Here, we systematically investigated the factors and mechanisms that govern the degradation of DNA on the nanoparticle surface in serum. We discovered that a higher DNA density, shorter oligonucleotides, and thicker PEG layer increased protection of DNA against serum degradation. Oligonucleotides on the surface of nanoparticles were highly resistant to DNase I endonucleases, and degradation was carried out exclusively by protein-mediated exonuclease cleavage and full-strand desorption. These results enabled the programming of the degradation rates of the DNA-assembled nanoparticle system from 0.1 to 0.7 h-1 and the engineering of superstructures that can release two different preloaded dye molecules with distinct kinetics and half-lives ranging from 3.3 to 9.8 h. This study provides a general framework for investigating the serum stability of DNA-containing nanostructures. The results advance our understanding of engineering principles for designing nanoparticle assemblies with controlled in vivo behavior and present a strategy for storage and multistage release of drugs and contrast agents that can facilitate the diagnosis and treatment of cancer and other diseases.

Keywords: DNA nanostructures; controlled cargo release; nanoparticle assembly; serum resistance; serum stability.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • DNA / chemistry
  • DNA Cleavage
  • Deoxyribonuclease I / analysis
  • Deoxyribonuclease I / blood
  • Drug Delivery Systems / methods*
  • Humans
  • Nanoparticles / chemistry*
  • Nanoparticles / statistics & numerical data
  • Nanostructures / analysis
  • Nanostructures / therapeutic use
  • Oligonucleotides / blood
  • Oligonucleotides / therapeutic use*
  • Polyethylene Glycols / chemistry
  • Serum

Substances

  • Oligonucleotides
  • Polyethylene Glycols
  • DNA
  • Deoxyribonuclease I